Literature DB >> 14732806

Monocyte apoptosis in uremia is normalized with continuous blood purification modalities.

Vincenzo D'Intini1, Valeria Bordoni, Irene Bolgan, Monica Bonello, Alessandra Brendolan, Carlo Crepaldi, Fiorella Gastaldon, Nathan W Levin, Rinaldo Bellomo, Claudio Ronco.   

Abstract

Uremia is associated with a state of immune dysfunction. Dysregulation of homeostasis may be directly related to abnormal apoptosis regulation in uremia, which is crucial for the maintenance of the biological system. We demonstrated that plasma from three groups of uremic subjects, i.e. hemodialysis (HD) patients, peritoneal dialysis (PD) patients and patients with predialysis chronic renal failure (CRF), has different apoptotic potential on U937 monocytes. The plasma of HD and CRF subjects when incubated with U937 cells induced higher levels of apoptosis compared with that of PD and control subjects (HD 26.08 +/- 11.39, CRF 24.87 +/- 9.07, PD 12.13 +/- 4.51, controls 11.69 +/- 4.02). Furthermore, the phagocytic ability of U937 cells incubated with the various plasma demonstrated an impaired response in the HD and CRF subjects (HD 27.56 +/- 6.67, CRF 30.24 +/- 9.08, PD 36.55 +/- 9.80, controls 40.04 +/- 6.98). These results suggest that continuous blood purification, such as in PD, may have advantages over intermittent therapies in removing uremic apoptotic molecules and potentially maintaining biological function and homeostasis. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732806     DOI: 10.1159/000074918

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

1.  Cardiorenal Syndrome Type 1 May Be Immunologically Mediated: A Pilot Evaluation of Monocyte Apoptosis.

Authors:  Grazia Maria Virzì; Rossella Torregrossa; Dinna N Cruz; Chang Y Chionh; Massimo de Cal; Sachin S Soni; Massimo Dominici; Giorgio Vescovo; Mitchell H Rosner; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2012-01-20       Impact factor: 2.041

2.  Moderate kidney disease inhibits atherosclerosis regression.

Authors:  Manish P Ponda; Irina Barash; Jonathan E Feig; Edward A Fisher; Edward Y Skolnik
Journal:  Atherosclerosis       Date:  2009-10-29       Impact factor: 5.162

Review 3.  Monocytes in Uremia.

Authors:  Matthias Girndt; Bogusz Trojanowicz; Christof Ulrich
Journal:  Toxins (Basel)       Date:  2020-05-21       Impact factor: 4.546

4.  Combination of Multiple Hemodialysis Modes: Better Treatment Options for Patients Under Maintenance Hemodialysis.

Authors:  Zhi-Yong Zhang; Ming-Xu Li; Hai Yu; Jun Zhao; Feng-Lin Xiao; Fang Xuan; Yi-Xin Zhao
Journal:  Ther Clin Risk Manag       Date:  2021-01-29       Impact factor: 2.423

Review 5.  Immune dysfunction in uremia—an update.

Authors:  Gerald Cohen; Walter H Hörl
Journal:  Toxins (Basel)       Date:  2012-10-24       Impact factor: 4.546

Review 6.  Recent evolution of renal replacement therapy in the critically ill patient.

Authors:  Claudio Ronco
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.